Stock Traders Buy High Volume of Call Options on Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the target of some unusual options trading activity on Monday. Stock investors purchased 2,563 call options on the company. This is an increase of 719% compared to the average volume of 313 call options.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $7.85 on Wednesday. The firm has a 50-day simple moving average of $8.40 and a two-hundred day simple moving average of $7.95. The firm has a market cap of $2.43 billion, a P/E ratio of -11.54 and a beta of 1.12. Amneal Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $9.48.

Wall Street Analysts Forecast Growth

AMRX has been the topic of several research reports. Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research note on Friday, September 6th. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Finally, Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the sale, the senior vice president now directly owns 13,665 shares in the company, valued at $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 17.46% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at $26,000. Gladius Capital Management LP bought a new stake in Amneal Pharmaceuticals in the 3rd quarter worth about $37,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at about $42,000. nVerses Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $62,000. Finally, Quest Partners LLC bought a new stake in shares of Amneal Pharmaceuticals in the third quarter worth approximately $84,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.